Epstein-Barr virus latent membrane protein 1 and 2 peptide-major histocompatibility complexes (EBV LMP1/2-pMHC)

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) and latent membrane protein 2 (LMP2) peptide-major histocompatibility complexes (pMHC) are specialized cell-surface targets found on EBV-infected tumor cells. These complexes are formed when intracellular viral oncogenes, LMP1 and LMP2, are processed into short peptides and presented by MHC Class I molecules, most commonly HLA-A*02:01 (PMID: 30233154). LMP1 and LMP2 play critical roles in maintaining viral latency and driving malignant transformation by mimicking CD40 signaling and modulating B-cell receptor pathways (PMID: 25407358). Because these viral proteins are absent in healthy, non-infected human tissues, their pMHC complexes serve as highly specific neoantigens for immunotherapy. Current therapeutic strategies include adoptive cell transfer of EBV-specific cytotoxic T-lymphocytes (CTLs), TCR-engineered T cells, and the development of TCR-like antibodies that recognize the specific peptide-HLA conformation (PMID: 26850127). These approaches aim to selectively eliminate malignant cells in diseases such as nasopharyngeal carcinoma and Hodgkin lymphoma while sparing normal tissue (PMID: 33403132). Clinical success with products like tabelecleucel has demonstrated the viability of targeting these complexes in patients with EBV-associated lymphoproliferative disorders (PMID: 29321061).

Other names

LMP1/LMP2-HLA complexesEBV-specific peptide-MHC complexesLMP1/2-MHC class I complexesEBV-associated pMHCLatent membrane protein peptide-HLA-A*02:01

Targeting of viral-derived peptides presented by MHC Class I molecules to induce T-cell mediated lysis or antibody-dependent cellular cytotoxicity against EBV-infected malignant cells.